Lipocine announces q1 2020 financial and operational results

Lipocine announces first quarter 2020 financial and operational results.q1 loss per share $0.14.resubmitted nda for tlando.fda acknowledged receipt of resubmission and established august 28, 2020 as pdufa goal date.received fda clearance on ind application for phase 2 clinical study with lpcn 1148 for treatment of nash in cirrhotic patients.
LPCN Ratings Summary
LPCN Quant Ranking